Cilengitide (EMD121974) and temozolomide with concomitant radiation therapy, followed by cilengitide and temozolomide maintenance therapy in subjects with newly diagnosed glioblastoma multiforme – a multicenter, open-label, uncontrolled Phase I/IIa study
- Registry ID
- EUCTR2004-004849-18
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Merck KGaA
- Start date
- 2005-06-24
- Last update
- 2026-08-16
Conditions
- Newly diagnosed Glioblastoma (Astrocytoma, WHO grade IV)
Summary
The primary objective of this exploratory study is to estimate the percentage of subjects who survived 6 months without disease progression (6-month PFS).
Locations
View on source registry